2Q PREVIEW: Obesity, orphan drug sales; M&A updates
This article was originally published in Scrip
Executive Summary
Second quarter earnings reports will be the first-ever opportunity for some companies to report drug sales data or quarter-to-quarter revenue increases, including some high-profile obesity therapies and newly approved treatments for orphan diseases.